Get App

Regeneron pauses drug trial on sickest

For the second time, a study testing an antibody drug for Covid-19 has been paused to probe a possible safety issue in hospitalised patients.
  • Updated On Oct 31, 2020 at 07:19 AM IST
Read by: 100 Industry Professionals
Reader Image Read by 100 Industry Professionals
For the second time, a study testing an antibody drug for Covid-19 has been paused to probe a possible safety issue in hospitalised patients. Regeneron said on Friday that independent monitors had recommended placing on hold enrollment of the most severely ill patients because of a potential safety problem and unfavourable balance of risks and benefits. Other studies in mild or moderately ill people are continuing. Earlier this month, a different group of monitors recommended pausing enrollment of hospitalised patients in a study testing an Eli Lilly antibody drug.
  • Published On Oct 31, 2020 at 07:19 AM IST
Be the first one to comment.
Comment Now

COMMENTS

Comment Now Read Comment (1)

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles
Scan to download App